top of page
Screen Shot 2023-04-27 at 3.10.37 PM.png

Lori Kunkel

Independent Director & K36 Board Member

Dr. Kunkel has more than two decades of experience in oncology and immunology drug development and commercialization. Dr. Kunkel presently serves on the Board of Directors of Curis, Inc., Nurix Therapeutics, and Oric Pharmaceuticals.  She also chairs the Scientific advisory boards of Atomwise, Elevation Oncology and Rain Therapeutics, and serves as a clinical advisor to Enliven Therapeutics, Indapta Therapeutics, Jasper Therapeutics, Oncopeptide, Inc and Oryzon, S.A. She was previously the acting Chief Medical Officer and served on the board of Loxo Oncology (sold to Eli Lilly). She was formerly Chief Medical Officer at Pharmacyclics (acquired by AbbVie) and CMO at Proteolix, Inc. (acquired by Onyx Pharmaceuticals), where she contributed to the global approvals of cancer therapeutics IMBRUVICA® and Kyprolis®, respectively.  Prior to joining the biotechnology industry, Dr. Kunkel spent ten years in academic medicine and served as a faculty member at the Bone Marrow Transplant Unit in the Division of Hematology/Oncology at University of California, Los Angeles.


Dr. Kunkel obtained a medical degree from University of Southern California and a bachelor’s degree in biology from University of California, San Diego. She is board certified in internal medicine and held board certifications in hematology and oncology.

bottom of page